Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 06, 2020

High-Dose Chemotherapy With HSCT for High-Risk Breast Cancer and Four or More Involved Axillary Lymph Nodes

JAMA Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial
JAMA Oncol 2020 Jan 30;[EPub Ahead of Print], TG Steenbruggen, LC Steggink, CM Seynaeve, JJM van der Hoeven, MJ Hooning, A Jager, IR Konings, JR Kroep, WM Smit, VCG Tjan-Heijnen, E van der Wall, AD Bins, SC Linn, M Schaapveld, JN Jacobse, FE van Leeuwen, CP Schröder, H van Tinteren, EGE de Vries, GS Sonke, JA Gietema

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading